Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.
DRD2
EGFR
ONC201
anti-DRD2 treatment
efficacy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
25 03 2021
25 03 2021
Historique:
pubmed:
25
8
2020
medline:
28
4
2021
entrez:
25
8
2020
Statut:
ppublish
Résumé
There are ongoing clinical trials exploring the efficacy of dopamine receptor D2 (DRD2) inhibition against glioblastomas, the most common primary brain tumor. Here we examine potential molecular determinants of this efficacy. The Cancer Genome Atlas glioblastoma database and other published mRNA profiles were used to analyze the DRD2 and epidermal growth factor receptor (EGFR) expression pattern. In vitro and in vivo responses to DRD2 inhibitors were determined using patient-derived xenograft (PDX) glioblastoma models. Immunohistochemical studies were performed on clinically annotated glioblastoma samples derived from patients treated with ONC201. Analysis of clinical glioblastoma specimens derived from independent patient cohorts revealed an inverse correlation between EGFR and DRD2 mRNA expression, with implication that signaling mediated by these proteins shares overlapping functions. In independent panels of PDX glioblastoma lines, high EGFR expression was associated with poor in vitro and in vivo response to DRD2 inhibitors, including haloperidol and ONC201. Moreover, ectopic expression of a constitutively active EGFR, variant (v)III, suppressed glioblastoma sensitivity to ONC201. DRD2 expression positively correlated with expression of rate-limiting enzymes for dopamine synthesis as well as dopamine secretion, suggesting contribution of autocrine DRD2 signaling. Analysis of specimens from patients treated with ONC201 (n = 15) showed an inverse correlation between the intensity of EGFR staining and clinical response. The median overall survival for patients with high and low EGFR staining was 162 and 373 days, respectively (0.037). High EGFR expression is a determinant of poor glioblastoma response to DRD2. This finding should inform future clinical trial designs.
Sections du résumé
BACKGROUND
There are ongoing clinical trials exploring the efficacy of dopamine receptor D2 (DRD2) inhibition against glioblastomas, the most common primary brain tumor. Here we examine potential molecular determinants of this efficacy.
METHODS
The Cancer Genome Atlas glioblastoma database and other published mRNA profiles were used to analyze the DRD2 and epidermal growth factor receptor (EGFR) expression pattern. In vitro and in vivo responses to DRD2 inhibitors were determined using patient-derived xenograft (PDX) glioblastoma models. Immunohistochemical studies were performed on clinically annotated glioblastoma samples derived from patients treated with ONC201.
RESULTS
Analysis of clinical glioblastoma specimens derived from independent patient cohorts revealed an inverse correlation between EGFR and DRD2 mRNA expression, with implication that signaling mediated by these proteins shares overlapping functions. In independent panels of PDX glioblastoma lines, high EGFR expression was associated with poor in vitro and in vivo response to DRD2 inhibitors, including haloperidol and ONC201. Moreover, ectopic expression of a constitutively active EGFR, variant (v)III, suppressed glioblastoma sensitivity to ONC201. DRD2 expression positively correlated with expression of rate-limiting enzymes for dopamine synthesis as well as dopamine secretion, suggesting contribution of autocrine DRD2 signaling. Analysis of specimens from patients treated with ONC201 (n = 15) showed an inverse correlation between the intensity of EGFR staining and clinical response. The median overall survival for patients with high and low EGFR staining was 162 and 373 days, respectively (0.037).
CONCLUSIONS
High EGFR expression is a determinant of poor glioblastoma response to DRD2. This finding should inform future clinical trial designs.
Identifiants
pubmed: 32830856
pii: 5896390
doi: 10.1093/neuonc/noaa188
pmc: PMC7992877
doi:
Substances chimiques
Receptors, Dopamine D2
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
400-411Subventions
Organisme : NINDS NIH HHS
ID : R01 NS080939
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS097649
Pays : United States
Organisme : NIGMS NIH HHS
ID : R44 GM128223
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Clin Cancer Res. 2019 Apr 1;25(7):2305-2313
pubmed: 30559168
Oncotarget. 2014 Feb 28;5(4):882-93
pubmed: 24658464
Oncotarget. 2019 Mar 1;10(18):1716-1728
pubmed: 30899443
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
ACS Chem Neurosci. 2013 Feb 20;4(2):321-9
pubmed: 23421683
Trends Pharmacol Sci. 2007 Dec;28(12):602-7
pubmed: 18001849
Cell. 2005 Jul 29;122(2):261-73
pubmed: 16051150
Genes Dev. 2007 Nov 1;21(21):2683-710
pubmed: 17974913
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Schizophr Res. 2005 Mar 1;73(2-3):333-41
pubmed: 15653279
Front Mol Neurosci. 2011 Nov 01;4:38
pubmed: 22065948
Trends Biochem Sci. 2014 Oct;39(10):465-74
pubmed: 25239057
Br J Pharmacol. 2003 Mar;138(5):775-86
pubmed: 12642378
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4055-64
pubmed: 26159421
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Clin Cancer Res. 2018 Nov 1;24(21):5392-5406
pubmed: 30037819
Stem Cells Int. 2015;2015:427518
pubmed: 26136784
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5724-9
pubmed: 9576951
Cancer Cell. 2018 Jul 9;34(1):163-177.e7
pubmed: 29990498
West J Med. 1991 Aug;155(2):152-63
pubmed: 1926844
Pharmacol Rev. 2011 Mar;63(1):182-217
pubmed: 21303898
Oncotarget. 2017 May 12;8(45):79298-79304
pubmed: 29108308
Ther Adv Med Oncol. 2016 Nov;8(6):421-428
pubmed: 27800031
J Neurosci. 2019 Mar 13;39(11):1982-1993
pubmed: 30651332
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Curr Cancer Drug Targets. 2017;17(3):290-296
pubmed: 28029074
Trends Neurosci. 2020 Mar;43(3):144-154
pubmed: 32044129
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cell. 2005 Jul 29;122(2):153-5
pubmed: 16051141
Mol Cell Neurosci. 2005 May;29(1):128-38
pubmed: 15866053
Cell Commun Signal. 2013 May 17;11(1):34
pubmed: 23683503
Neuro Oncol. 2016 Oct;18(10):1367-78
pubmed: 27116978
Trends Cell Biol. 2016 Apr;26(4):262-271
pubmed: 26671200
ACS Chem Biol. 2019 May 17;14(5):1020-1029
pubmed: 31021596
Int J Cancer. 2017 Dec 1;141(11):2348-2358
pubmed: 28801914
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2616-21
pubmed: 20133782
Genes Dev. 2012 Apr 15;26(8):756-84
pubmed: 22508724
Sci Rep. 2017 Aug 22;7(1):9043
pubmed: 28831081
Genome Res. 2012 Feb;22(2):398-406
pubmed: 21908773
Nat Commun. 2019 Jul 2;10(1):2910
pubmed: 31266951
Annu Rev Pathol. 2006;1:97-117
pubmed: 18039109
Cell. 2014 Aug 28;158(5):973-975
pubmed: 25171399
Trends Genet. 2012 Apr;28(4):155-63
pubmed: 22342180
J Exp Clin Cancer Res. 2019 May 23;38(1):219
pubmed: 31122294
CNS Drugs. 2017 Sep;31(9):723-735
pubmed: 28791656
Mol Cancer Ther. 2007 Mar;6(3):1167-74
pubmed: 17363510
Sci Transl Med. 2013 Feb 6;5(171):171ra17
pubmed: 23390247
Adv Cancer Res. 2018;138:99-142
pubmed: 29551131
Nat Protoc. 2006;1(2):581-5
pubmed: 17406285